COMPANY
Foli Bio
Foli Bio brings together expertise in host transcriptomics, gut biology, assay development, bioinformatics, and translational partnerships to advance stool-derived host RNA into research and diagnostic applications. From company website Source · checked 2026-10-19
Sources for this description (1)
- Foli Bio brings together expertise in host transcriptomics, gut biology, assay development, bioinformatics, and translational partnerships to advance stool-derived host RNA into research and diagnostic applications.
- “Foli Bio brings together expertise in host transcriptomics, gut biology, assay development, bioinformatics, and translational partnerships to advance stool-derived host RNA into real-world research and diagnostic applications.” https://foli.bio/about/ (2026-10-19)
Funding and NIH signals
- NIH award NIH awarded $400K (SBIR Phase I 1R43HG014430-01A1, new, notice Sep 17, 2026). NIH RePORTER 1R43HG014430-01A1 (Sep 17, 2026)
Evidence (1 event)
- Sep 17, 2026 · NIH RePORTER 1R43HG014430-01A1
Organization: FOLI BIO INC.; City/State: NEW YORK, NY; Project number: 1R43HG014430-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 399875; Administering IC: National Human Genome Research Institute; Project title: Development of fecal exfoliome sequencing as a multi-omics approach for gut health management; Organization type: Domestic For-Profits
- Sep 17, 2026 · NIH RePORTER 1R43HG014430-01A1